What question did this study set out to answer?

Evaluate the effectiveness and safety of orelabrutinib combined with other agents in PCNSL patients unfit for intensive chemotherapy.

December 11, 2025Open Access

Effectiveness and safety of orelabrutinib combined with rituximab, temozolomide, methotrexate, and cytarabine in intensive chemotherapy-unfit patients with PCNSL in China

Puntos clave

Evaluate the effectiveness and safety of orelabrutinib combined with other agents in PCNSL patients unfit for intensive chemotherapy.
Retrospective study design
Involved patients with primary CNS lymphoma
Combination of orelabrutinib, rituximab, temozolomide, methotrexate, and cytarabine
The ORT-M/A regimen was efficacious
The treatment was well-tolerated by patients
Provides a potential therapeutic strategy for unfit PCNSL patients

Resumen

The ORT-M/A chemotherapy regimen was efficacious and well-tolerated in our patients with PCNSL. This retrospective study provided a potential therapeutic strategy for PCNSL patients who are unfit for intensive chemotherapy and warrant further investigation.

Leer artículo completoexternamente

Me gusta

Guardar

Ver artículo completo

Cite This Study

Fang et al. (Thu,) studied this question.

synapsesocial.com/papers/69401b172d562116f28f72f5 https://doi.org/https://doi.org/10.1186/s40001-025-03657-2

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

Me gusta

Guardar

Ver artículo completo